MarketPulse
A

$ACRS

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Aclaris Therapeutics, Inc.

Aclaris to Present Phase 2a ATI-2138 Data at 2026 AAD Meeting

Aclaris Therapeutics will present previously unreported Phase 2a trial results for ATI-2138, an oral dual ITK/JAK3 inhibitor, at the 2026 AAD Annual Meeting in Denver.
ACRSclinical trial resultsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis